Journal of Digital Convergence (디지털융복합연구)

The Society of Digital Policy and Management (한국디지털정책학회)
권호 표지
DOI QR코드

DOI QR Code

A convergence Study on Associated Factors on Metabolic Syndrome among Inpatients with Schizophrenia

조현병 입원환자의 대사증후군 관련요인에 대한 융복합연구

  • Received : 2018.08.07
  • Accepted : 2018.10.20
  • Published : 2018.10.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of the study was to identify the associated factors on the metabolic syndrome among inpatients with schizophrenia. Methods: The participants were 127 inpatients with schizophrenia from G mental hospital in G city. Collected data were analized with SPSS 22.0 using descriptive statistics, ${\chi}^2$-test, t-test and logistic regression. Results: Metabolic syndrome prevalence of the participants was 46.5%. There were statistically significant differences according to physical disease (${\chi}^2=11.51$, p<.001), body mass index (${\chi}^2=13.59$, p<.001), perception of obesity (${\chi}^2=8.38$, p<.001), and taking olanzapine (${\chi}^2=6.31$, p<.05). Conclusion: Based on the study results, the nursing intervention for prevention and management of metabolic syndrome is needed to develop and provide to schizophrenia patients.

본 연구는 조현병 입원환자를 대상으로 대사증후군 위험성 정도를 파악하고 관련요인을 파악하기 위한 서술적 상관 관계연구이다. 연구대상자는 G 광역시에 위치한 G 정신병원 조현병 입원환자 127명이다. 수집된 자료는 SPSS 22.0을 이용하여 기술통계, ${\chi}^2-test$, t-test, 로지스틱회귀분석을 실시하였다. 본 연구결과 대사증후군 유병율은 46.5%로 높게 나타났다. 대상자의 대사증후군은 신체질환 유무(${\chi}^2=11.51$, p<.001), 체질량 지수(${\chi}^2=13.59$, p<.001), 비만 인식(${\chi}^2=8.38$, p<.001), 올란자핀 복용(${\chi}^2=6.31$, p<.05)에서 통계적으로 유의한 차이가 있었다. 회귀분석 결과, 대사증후군 발생 위험도는 신체질환이 있는 경우 3.65배(95% CI=1.68~7.92), 체질량지수가 23이상인 경우 3.76배(95% CI=1.39~10.14), 올란자핀을 복용하는 경우 3.05배(95% CI=1.02~9.10) 더 증가하는 것으로 나타났다. 이 모형의 설명력은 총 29.1%로 나타났다. 따라서 본 연구에서 확인된 조현병 입원환자의 대사증후군 관련요인을 토대로 체계적인 대사증후군 관리와 예방을 위한 간호중재의 개발 및 제공이 요구된다.

Keywords

References

  1. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, & Poirier P. (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis, Journal of the American College of Cardiology, 56(14), 1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034
  2. H. S. Jang. (2012). There lationship between metabolic syndrome,its components, and cancer incidence in Korean, Unpublished doctoral dissertation, University of Ulsan, Ulsan.
  3. J. I. Chang. (2009). Effects of Metabolic Syndrome on Chronic Kidney Disease. Korean Journal of Urology, 50(3), 261-266. https://doi.org/10.4111/kju.2009.50.3.261
  4. Glassman AH & Bigger JT Jr. (2001). Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry, 158, 1774-82. https://doi.org/10.1176/appi.ajp.158.11.1774
  5. National Rehavilitation Center Rehabilitation Institute. (2016). Disability and Health Statistics. Seoul : National Rehavilitation Center.
  6. K. D. Kang, Y. H. Sea & B. H. Yoon. (2012). Prevalence of Metabolic Syndrome in Chronic Schizophrenic Inpatients. Journal of The Korean Society of Biological Therapies in Psychiatry, 18(2), 281-289.
  7. I. S. Yun, H. S. Go & S. Y. Lee. (2011). A Study of Quality of Life and Body Image in Schizophrenia Patients with Metabolic Syndrome. Clinical psychopharmacology and neuroscience, 22, 208-213.
  8. J. K. Park, S. H. Kweon, Y. H. Kim, M. J. Jang & K. G. Oh (2012). Dietary Behaviors Related to Metabolic Syndrome in Korean Adults. Korean J Community Nutr 17(5), 664-675. https://doi.org/10.5720/kjcn.2012.17.5.664
  9. J. W. Roh, Y. S. Cho & A. H. Cho. (2011). The Prevalence of Metabolic Syndrome Among Inpatients with Schizophrenia. Korean Journal of Biological Psychiatry, 18(1), 46-54.
  10. W. J. Kim et al. (2011). Body Weight and Metabolic Changes in First-Episode Psychotic Patients with Antipsychotics Use : A Retrospective Study, Journal of the Korean Society of Biological Therapies, 17(2), 229-238.
  11. Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T & Carbon M. (2016). Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA psychiatry, 73(3), 247-59. https://doi.org/10.1001/jamapsychiatry.2015.2923
  12. Wildgust H. J. & Beary, M. (2010). Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacology, 24, 37-50. https://doi.org/10.1177/1359786810384639
  13. DE Hert M, Correll CU & Bobes J, Cetkovich-Bakmas M, Cohen D & Asai I. (2011). Physical illness in A patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care, World psychiatry, 10, 52-77. https://doi.org/10.1002/j.2051-5545.2011.tb00014.x
  14. S. M. Lee, I. H. Shim, Y. S. Woo, J. T. Yeon & W. Y. Park. (2014). A Trend of Medication Prescription Pattern for Outpatients with Bipolar Disorder in a University Hospital: Focusing on Atypical Antipsychotics, Clinical psychopharmacology and neuroscience, 25(3), 124-133.
  15. S. H. Lee & S. H. Cho. (2015). Factors Influencing Metabolic Syndrome among Mental Health Facility Patients with Schizophrenia, J Korean Acad Psychiatr Ment Health Nurs, 25(1), 1-10.
  16. S. M. Joo & K. H. Lee. (2012). Effect of smoking on heart rate variability in patients with schizophrenia, Keimyung Journal of Nursing Science, 16(2), 33-41.
  17. M. O. Kim, H. J. Lee, E. J. Park & K. H. Lee. (2010). Nutrient Intake and Risk of Metabolic Syndrome in Male Smokers. Korean Joutnal of Cpmmunity Nutrition, 15(6), 783-795.
  18. Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B & Woods SW. (2011). Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res, 127, 257-61. https://doi.org/10.1016/j.schres.2010.12.008
  19. Saha S, Chant D & McGrath J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry, 64, 1123-1131. https://doi.org/10.1001/archpsyc.64.10.1123
  20. M. K. Park et al. (2012). The Association between Smoking and Prolonged QT Intervals in Schizophrenic Patients. Joutnal of the Korean Society of Biological Therapies in Psychiatry, 18(2), 238-245.
  21. K. R. Park & Y. C. Cho. (2016). Prevalence Rates of Risk Factors of Metabolic Syndrome, and Its Related with Obesity Indices Among the Health Checkup Examinees. Journal of the Korea Academia-Industrial cooperation Society, 17(3), 153-162. https://doi.org/10.5762/KAIS.2016.17.3.153
  22. U. Y. Jang et al. (2014). Changes of Body Weight and Metabolic Syndrome in Psychiatric Inpatients ,Clinical psychopharmacology and neuroscience, 25(4), 207-216
  23. Y. Y. Nam, C. S. Kim, C. W. Ahn, K. M Park, B. Ryu, C. H. Kim (2006). Clinical Correlates of Metabolic Syndrome in Patients with Chronic Schizophrenia, Clinical psychopharmacology and neuroscience, 17(4), 335-341.
  24. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R & De Hert M.(2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis, Schizophr Bull, 39(2), 306-18. https://doi.org/10.1093/schbul/sbr148
  25. S. U. Lee. (2017). Risk factors for relapse and physical illness in patients with first-episode schizophrenia. Unpublished doctoral dissertation, Kyung Hee University, Seoul.
  26. H. S Cha & H. J. Park. (2016). Effects of Auricular Acupressure on Obesity in Women with Abdominal Obesity. Journal of Korean Academy of Nursing, 46(2), 249-259. https://doi.org/10.4040/jkan.2016.46.2.249
  27. S. G. Min. (2015). Modern psychiatry(6th Edition ). Seoul: ilchokak.
  28. J. S. Lee, J. Y. Kim, J. H. Ann & C. Y. Kim. (2005). Diabetic Ketoacidosis in a Schizophrenic Patient Treated with Olanzapine : A Case Report, Journal of the Korean Neuropsychiatric Association, 44(1), 116-119.
  29. Pramyothin P & Khaodhiar L. (2010). Metabolic syndrome with the atypical antipsychotics, Curr Opin Endocrinol Diabetes Obes, 17, 460-466. https://doi.org/10.1097/MED.0b013e32833de61c
  30. S. H. Kim et al. (2010). Effect of Weight Control Program for Psychiatric Inpatient on Atypical Antipsychotics. Journal of Korean Academy of Nursing, 10(1), 286-286.